TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Written Informed Consent~* Age≥ 17 and \<80 years,~* Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment)~* Oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment)~* HbA1c ≥ 7.0% and ≤10.0%~Exclusion Criteria:~* Women of child bearing potential~* body mass index (BMI)≥35 Kg/m2 or BMI \<18.5 Kg/m2~* Hemoglobin A1c (HbA1c)\>10.0% or \<7.0%~* Active liver disease and/or significant abnormal liver function~* Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma~* Congestive heart failure defined as New York Heart Association (NYHA) class III or IV and /or left ventricular ejection fraction ≤40%~* Significant cardiovascular history with the past 6 months~* Severe retinopathy, persistent uncontrolled hypertension (SBP≥180mmHg, or DBP≥105mmHg)~* Severe chronic gastrointestinal disease~* History of alcohol abuse or illegal drug abuse within the past 12 months~* Diagnosed anemia~* Creatine kinase ≥3 X ULN~* Serum creatinine ≥1.5 mg/dL(133μmol/L) \[males\], ≥1.4 mg/dL(124 μmol/L)\[females\]~* Alanine amino transferase (ALT) and/or aspartate amino transferase (AST)\> 1.5 X ULN and/or total bilirubin \> 2 X ULN~* Hemoglobin \<12g/dL \[males\], \<11g/dL \[females\]~* Allergies and Adverse Drug Reactions~* Prohibited Treatments and/or Therapies~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness~* Subjects decline to participate

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): Normal Weight by Body Weight Index
- A2 (Type: EXPERIMENTAL): Overweight by Body Weight Index
- A3 (Type: EXPERIMENTAL): Obese by Body Weight Index

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of CF~* FEV1 greater than or equal to 75% of predicted normal for age, gender, and height~* oxyhemoglobin saturation greater than or equal to 90%~* clinically stable~Exclusion Criteria:~* abnormal renal or liver function~* clinically significant findings atypical for moderate cystic fibrosis

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients at risk of developing OHSS, defined by the development of 20-30 follicles larger than 12 mm in diameter and retrieval of more than 20 oocytes~* ovarian stimulation with long protocol~Exclusion Criteria:~* coasting cases

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: SHAM_COMPARATOR): Receive human albumin 20% infusion
- Cabergoline (Type: EXPERIMENTAL): Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Holter Study (Continuous Glucose Monitoring) -

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus (DM) willing to perform SMBG at least 6 times daily to use the MiniMed CGMS for up to 3 consecutive days on 2 occasions.~* HbA1c: 6.5 to 9% with metformin monotherapy for a least 3 months~Exclusion Criteria:~* Age \>= 80 years~* BMI \<= 22 and \>=40 kg/m2~* Secondary T2 DM~* Hepatic failure, ASAT/ALAT\>3 ULN, and moderate/severe renal failure (CI \< 50 ml/min) CHF III \& IV~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Sitagliptin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (\>17 y.o.)~2. Antiretroviral-naïve.~3. Be able to comply with protocol requirements and instructions.~4. Subject or the subject's representative capable of giving signed informed consent~Exclusion Criteria:~1. Women who are breastfeeding or plan to become pregnant during the study.~2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.~3. Patients with anticipated need to change the ART before study ending.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): HIV-1 infected adults, ART-naive subjects, who start BIC/FTC/TAF using test and treat strategy recruited at infectious diseases units from various Spanish public healthcare centers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Juvista (Avotermin) in Scars Following Varicose Vein Removal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between 18 and 85 years of age.~* Patients undergoing surgical removal of bilateral varicose veins by ligation and stripping, which will result in clinically similar (i.e. size and location) wounds at the groin and knee.~* Patients who have provided written informed consent.~* Patients with a body mass index between 15 and 35 kg/m2 inclusive.~* Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol (see Protocol Section 6.4.1).~* Female patients of child bearing potential using method(s) of contraception acceptable to the Investigator and who agree to do so from at least the screening visit until one month after administration of the Investigational Medicinal Product.~Exclusion Criteria:~* Patients who have had previous surgical treatment for varicose veins.~* Patients with a history of a bleeding disorder.~* Patients with a chronic or currently active skin disorder which may adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.~* Patients who on direct questioning and/or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.~* Patients who are taking or have taken investigational drugs in the 3 months prior to the screening visit.~* Patients with existing scars within 3cm of the potential trial wounds.~* Patients with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerability or efficacy of the Investigational Product.~* Patients with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.~* Patients who are taking regular, continuous, oral corticosteroid therapy.~* Patients undergoing investigations or changes in management for an existing medical condition.~* Patients who are pregnant or lactating.~* Patients who, in the opinion of the Investigator, are not likely to complete the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or older, of either gender~* Patients must be tested positive for SARS-CoV-2 by RT-PCR~* Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.~* Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening~* Patients must be under the care of a Physician for diagnosis of COVID-19~* Patients who have signed informed consent~Exclusion Criteria:~* Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin~* Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis~* Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure~* Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.~* Patients with gallstone obstruction~* Hypothyroid suppering patients~* Patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/L);~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): This arm will receive the standard of care as per the hospital guidelines.
- Investigational treatment (Type: EXPERIMENTAL): This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* 12 to 15 months of age~* Negative clinical history to measles, mumps, rubella, varicella and/or zoster~* Received only the 3-dose primary series of a pneumococcal conjugate vaccine with at least 2 months prior to the receipt of any of the study vaccines~* Signed consent~Exclusion Criteria:~* Previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination~* Any condition resulting in depressed immunity~* Any allergy to any vaccine component as stated in the package circulars~* Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination~* History of seizure disorder~* Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days~* Recent febrile illness

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
- 2 (Type: EXPERIMENTAL): Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
- 3 (Type: EXPERIMENTAL): Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Risk Reduction in Subutex Injectors in Tbilisi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current opioid dependence;~* injecting buprenorphine 10 or more times in the last 30 days;~* between 25 and 50 years of age;~* buprenorphine and/or opiate positive urine test;~* not on methadone maintenance in last 4 weeks;~* stable address within Tbilisi and not planning to move;~* home or cellular phone number where can be reached;~* able to provide name of family member who knows whereabouts;~* willingness and ability to give informed consent.~Exclusion Criteria:~* currently dependent on alcohol, benzodiazepines or other CNS depressants;~* legan charges with impending incarceration;~* plans to move from Tbilisi within next 6 months;~* current participation in another treatment study;~* serious medical problems that would impair or make hazardous ability to participate;~* active TB;~* currently psychotic/suicidal;~* uncontrolled seizure disorder.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Methadone maintenance for 12 weeks (Type: ACTIVE_COMPARATOR): Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
- buprenorphine-naloxone (Suboxone) (Type: ACTIVE_COMPARATOR): 12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary breast cancer~* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy~* ≥19 years of age~* Able to provide verbal consent~Exclusion Criteria:~* Contraindication to Filgrastim

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neupogen for 5 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 5 days
- Neupogen for 7 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 7 days
- Neupogen for 10 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has qualified for and completed either study 06-009 (NCT00423813) or 06-008 (NCT00371137).~* Subject is able, in the opinion of the investigator, to take Xyrem® for approximately 9-1/2 months.~Exclusion Criteria:~* Subject terminated early from either study 06-009 or 06-008.~* Subject experienced any serious adverse event related to study drug in either study 06-009 or 06-008.~* Subject, in the opinion of the investigator, experienced an adverse event in 06-009 or 06-008 that may prevent him/her from safely participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subjects able to give consent~* Post partum patients~* Baseline Hbg\< /= 10~* Agree to practice birth control~* Demonstrate willingness to comply with protocol restrictions~Exclusion Criteria:~* Known hypersensitivity reaction to oral or IV iron (VIT-45)~* Documented history of discontinuing oral iron~* Significant bleeding~* History of anemia other that iron deficiency anemia~* Severe Psychiatric disorders~* Active severe infection~* Known Hepatitis B antigen or Hep C viral antibody or active hepatitis~* Known HIV antibody~* Received investigational product within 30 days~* Alcohol abuse~* Hemochromatosis or other iron storage disorder

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIT-45 (Type: EXPERIMENTAL): A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
- Oral iron tablets (Type: ACTIVE_COMPARATOR): 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Class III or IV heart failure for at least 3 months~* Left ventricular ejection fraction less than or equal to 40%~* Currently being treated for heart failure with standard therapies for at least one month~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Inability to take oral medications~* Uncontrolled hypertension, bradyarrhythmias or tachyarrhythmias~* Hypertrophic obstructive cardiomyopathy~* Severe obstructive pulmonary disease~* Significant renal impairment~* Significant uncorrected valvular or congenital heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Hospitalized patients among patients having a visit record with a confirmed diagnosis of NVAF (ICD-10 Code: I48) and prescribed dabigatran or warfarin in the hospitalization period~Exclusion criteria:~1. Having a record with a diagnosis of atrial flutter, valvular atrial fibrillation or postoperative atrial fibrillation diagnosis as standard disease name during the study period.~2. Having a record with a diagnosis of rheumatic atrial fibrillation (ICD-10 code I05 to I09 \[chronic rheumatic atrial fibrillation\])or mechanical-valvular atrial fibrillation (ICD-10 code T820 \[artificial cardiac valve mechanical complication\]) during the study period.~3. Having a record with a confirmed diagnosis of cancer (ICD-10 code C00-C97 \[malignant neoplasm\]) during the study period.~4. Having a record of dialysis (class J038 artificial kidney) during the study period.~5. Having a record of dabigatran use for a purpose other than prevention of ischemic stroke and systemic embolism in non-valvular atrial fibrillation patients.~6. Having a record of dabigatran or warfarin before the hospitalization~7. Having a record of new diagnosis of atrial fibrillation after the initiation of dabigatran or warfarin treatment in the hospitalization period.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-Valvular Atrial Fibrillation (Type: None): None
- acute ischemic stroke (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Untreated mantle cell lymphoma~Exclusion Criteria:~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete